RadNet’s Artificial Intelligence Subsidiary, DeepHealth, Announces FDA Clearance for its AI Mammography Triage Software
CAMBRIDGE, Mass. and LOS ANGELES, April 19, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc., (NASDAQ: RDNT) today announced that its subsidiary DeepHealth, a leading developer of artificial intelligence (AI) for mammography interpretation, has received FDA clearance for its mammography triage software Saige-Q.
Saige-Q is a screening worklist prioritization tool that enables radiologists to more effectively manage their mammography cases with the use of artificial intelligence. DeepHealth’s powerful new AI technology automatically identifies suspicious screening exams that may need prioritized attention, allowing radiologists to optimize their workflow for efficiency and effectiveness.
“Saige-Q is built using our core artificial intelligence algorithms, described in a recent article in Nature Medicine,” said Bill Lotter, Ph.D., CTO, and co-founder of DeepHealth. “As the first FDA-cleared mammography triage product that supports 3D mammography in addition to 2D mammography, Saige-Q demonstrates high performance that is maintained across different breast densities and lesion types.”
“As our first FDA-cleared product, Saige-Q is a major milestone for our team. It represents the first step of many towards delivering the best care possible for patients through rigorous science that clinicians and patients can trust,” said Gregory Sorensen, M.D., CEO, and co-founder of DeepHealth. “We have developed an advanced algorithm to support radiologists with the significant challenge of finding breast cancer as early as possible. Saige-Q empowers radiologists to optimize how and when they read cases marked by Saige-Q as suspicious or those not marked as suspicious, enhancing their ability to deliver the best care.”
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “Receiving FDA clearance for our first mammography AI software algorithm is an important step in RadNet’s commitment to delivering the best quality of care for our patients. With the almost 2 million mammography exams we perform annually in our markets, we will now begin to deploy this tool, enabling our mammographers to become more accurate and productive. The efficiency gains and accuracy should be further enhanced by a more advanced diagnostic algorithm we plan to submit to the FDA for its review by year end.”
“With the purchase of DeepHealth last year and the ongoing investments we are making in AI, we are dedicated to leading the transformation of our industry into utilizing machine learning to enhance patient outcomes, improve the productivity of radiologists and offer unique screening programs to health insurers which we believe will have a profound impact on population health and wellness,” Dr. Berger noted.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 331 owned and/or operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, New Jersey, Arizona, Florida, and New York. In addition, RadNet provides radiology information technology solutions and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has approximately 8,200 employees.
For more information, visit www.radnet.com.
About DeepHealth, Inc.
DeepHealth, a wholly owned subsidiary of RadNet, Inc., uses machine learning to distill lifetimes of insights from medical experts into software to assist physicians. DeepHealth’s mission is to enable the best care by providing products that clinicians and patients can trust, through rigorous science and clinical integration. For more information, visit www.deep.health.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.
CONTACTS:
Media Contact – DeepHealth, Inc.:
Bret Baird
Chief Commercial Officer
424-832-1480
bbaird@deep.health
Media Contact – RadNet, Inc.:
Mark Stolper
Executive Vice President and Chief Financial Officer
310-445-2800
Mark.stolper@radnet.com